Physician profile
Alan Ruiz
NPI 1407099484
$5,332.31
in general payments reported to CMS, 2019-2025
34 companies · $1,016 in 2025
The $1,016 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $801 · 2020: $676 · 2021: $503 · 2022: $798 · 2023: $819 · 2024: $719 · 2025: $1,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,554.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,160.57 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Novo Nordisk INC | $786.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $485.19 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $402.31 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $365.66 | 2019-2024 | Tradjenta, Jardiance |
| Astellas Pharma US INC | $226.37 | 2019-2024 | Veozah, Myrbetriq |
| Biohaven Pharmaceutical Holding Company LTD. | $161.46 | 2022 | |
| Phathom Pharmaceuticals, INC. | $156.98 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $155.01 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $147.16 | 2020-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $135.04 | 2022-2024 | |
| Abbott Laboratories | $117.09 | 2023-2024 | Freestyle Libre 3 |
| Vanda Pharmaceuticals INC. | $110.66 | 2024-2025 | Fanapt |
| Indivior INC. | $107.62 | 2023-2025 | Sublocade |
| Sanofi-Aventis U.S. LLC | $96.29 | 2020-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $92.85 | 2020-2025 | Evenity |
| Otsuka America Pharmaceutical, INC. | $76.85 | 2023-2025 | Rexulti |
| Orexo US, INC. | $71.16 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $52.09 | 2024-2025 | Opsumit, Uptravi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.64 | 2024 | Caplyta |
| Merck Sharp & Dohme LLC | $46.31 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $43.66 | 2022 | |
| Allergan, INC. | $42.62 | 2020 | |
| Eisai INC. | $35.56 | 2021 | |
| Currax Pharmaceuticals LLC | $32.37 | 2020-2024 | Contrave |
| Resmed Corp | $30.24 | 2024 | |
| Endo Pharmaceuticals INC. | $22.41 | 2021 | |
| Braeburn INC. | $21.90 | 2025 | Brixadi |
| Viatris Specialty LLC | $17.67 | 2025 | Yupelri |
| Gilead Sciences, INC. | $17.23 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.83 | 2021 | |
| Therapeuticsmd, INC. | $16.22 | 2019 | |
| Lilly USA, LLC | $15.57 | 2021 | |
| Lundbeck LLC | $14.75 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Ruiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.